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Abstract 
Introduction: Galcanezumab, a humanized monoclonal antibody binding calcitonin gene-related peptide, 
in development for migraine prevention. 
Methods: In this global, double-blind, 6-month study of  patients with episodic migraine, the intent to 
treat population included 915 patients randomized to monthly subcutaneous injections of galcanezumab 
120 mg (N=231) or 240 mg (N=223) or placebo (N=461). Primary endpoint was overall mean change 
from baseline in monthly migraine headache days. Key secondary endpoints were ≥50%, ≥75%, and 
100% response rates; monthly migraine headache days with acute migraine medication use; Patient 
Global Impression of Severity rating; and the Role Function-Restrictive of the Migraine-Specific Quality 
of Life questionnaire.  
Results: Mean monthly migraine headache days were reduced by 4.3 and 4.2 days by galcanezumab 120 
and 240 mg, respectively, and 2.3 days by placebo. Both doses were also superior to placebo for all key 
secondary endpoints. Injection site pain was the most common treatment-emergent adverse event, 
reported at similar rates in placebo and galcanezumab treatment groups. Both galcanezumab doses had 
significantly more injection site reactions and injection site pruritus, and the 240 mg group had 
significantly more injection site erythema relative to placebo. 
Conclusions: Galcanezumab 120 or 240 mg given once monthly was efficacious, safe, and well tolerated.  
Study identification: EVOLVE-2; NCT02614196; 
https://clinicaltrials.gov/ct2/show/NCT02614196?term=LY2951742%2C+cgah&rank=1 
Introduction 
The worldwide prevalence of migraine and its associated socioeconomic cost are well recognized (1-3). 
Despite its heavy burden, migraine is commonly inadequately treated (4,5). For example, the American 
Migraine Prevalence and Prevention study revealed that 54% of patients with migraine needed bed rest or 
reported severe impairment, and 39% reported some impairment (6). Moreover, although prevention 
treatment was indicated in 39% of patients with migraine, only 13% received it (6). In addition, up to 
68% of patients who use preventive medications stop doing so within 6 months because of insufficient 
benefit, dissatisfaction with the drug, or poor tolerability (7-9). There is a significant need for new 
treatment options with improved efficacy and tolerability.  
Over the past 3 decades, clinical investigations have pointed to the critical role of calcitonin gene-related 
peptide (CGRP) in migraine pathophysiology (10-13). This neuropeptide is expressed throughout the 
peripheral and central nervous systems and is prominent within the trigeminovascular system (12). It has 
been implicated in sensory neuromodulation, vasodilation, and mediation of neurogenic inflammation 
(12-14). Several studies demonstrated that migraine attacks are accompanied by elevated blood levels of 
CGRP, and the infusion of CGRP induces headache in individuals with migraine (10,11,15-17). Selective 
antagonists to the CGRP receptor were efficacious in clinical trials for acute migraine (12). 
Galcanezumab is a humanized monoclonal antibody that binds CGRP and prevents its biological activity 
without blocking the CGRP receptor. Two Phase 2 clinical trials have shown that galcanezumab, given in 
monthly doses ranging from 120 to 300 mg, was safe and efficacious in migraine prevention (18,19). In 
the current manuscript, we hypothesized that at least one dose of galcanezumab was superior to placebo 
over a 6-month dosing regimen. Accordingly, we provide the results of a large, global, Phase 3 trial of 
galcanezumab that confirms its efficacy and safety in patients with episodic migraine. 
Methods 
Study Design 
EVOLVE-2 (NCT02614196) was a Phase 3, multi-center, placebo-controlled, double-blind, randomized 
clinical trial analyzing the efficacy and safety of two dosing regimens of galcanezumab in patients with 
episodic migraine. This study was conducted between January 2016 and March 2017 at 109 study sites in 
the United States, United Kingdom, Netherlands, Spain, Czech Republic, Germany, Argentina, Israel, 
Korea, Taiwan, and Mexico. Of these sites, 49 (45%) were in the US. The study was composed of 4 study 
periods (Figure 1). Study Period I consisted of medical examination and washout of migraine preventive 
medications for at least 30 days (4 months for onabotulinumtoxin A). Study Period II was a 1-month 
baseline period that was used to establish the baseline number of migraine headache days (MHDs). Study 
Period III was a 6-month double-blind treatment phase. During the post-baseline periods, patients were 
allowed to take acute migraine medications as needed, with the exception of medications containing 
opioids or barbiturates, which were limited to no more than 3 times per month. Study Period IV was a 4-
month post-treatment (washout) period and is not a topic of this manuscript. Key elements of the protocol 
are available at https://clinicaltrials.gov/ct2/show/NCT02614196?term=LY2951742%2C+cgah&rank=1. 
A minimum of 825 patients were planned for this study, randomized in a 2:1:1 ratio of placebo to 
galcanezumab 120 mg/month or 240 mg/month (target of 206 patients).  It was estimated based on Monte 
Carlo simulations that this sample size would provide approximately 95% power that at least 1 dose level 
of galcanezumab would separate from placebo on the primary endpoint, at an overall one-sided 0.025 
significance level, assuming a standardized treatment effect size of 0.33 and a 26% discontinuation rate.    
Inclusion Criteria: 
To be enrolled in the study, patients had to be between the ages of 18 and 65 years (inclusive) and have a 
diagnosis of migraine with or without aura (1.1 and 1.2), as defined by International Headache Society 
(IHS) International Classification of Headache Disorders, 3rd edition, (ICHD-3) beta version (3). Patients 
were enrolled into the study by being approached by study staff, or through referral or advertising. 
Included patients had a history of migraine for at least 1 year prior to enrollment and with migraine onset 
prior to age 50 years. Patients also had to have 4 to 14 MHDs (including probable MHD), at least 2 
migraine attacks during the baseline period, and an 80% compliance rate in using the electronic diary 
(ePRO). Finally, patients had to agree to use an acceptable method of birth control during the study and 
for at least 5 months after receiving the last dose. The study protocol was reviewed and approved by the 
appropriate institutional review board for each of the study sites, and the study was conducted according 
to Good Clinical Practice and the Declaration of Helsinki guidelines. Patients provided written informed 
consent before undergoing study procedures. Investigators at each study site evaluated and confirmed 
eligibility, obtained consent and enrolled the patients. 
Exclusion Criteria 
Patients were excluded if they had failed treatment with 3 or more migraine prevention drugs from 
different classes (level A or B evidence per American Academy of Neurology guidelines for episodic 
migraine prevention) (20) or if they were using opioids or barbiturates more than twice per month. Other 
conditions leading to exclusion were participation in another clinical trial within the past 30 days, prior 
exposure to galcanezumab or any another CGRP antibody, taking any therapeutic antibody in the past 12 
months, known hypersensitivity to multiple drugs, or presence of any medical or psychiatric illness that 
would preclude study participation.  
Randomization and Blinding 
Randomization to double-blind treatment was performed at Visit 3. Patients were assigned in a double-
blind manner by a computer-generated randomization sequence using an interactive web-response system 
(IWRS) to placebo or galcanezumab 120 or 240 mg (2:1:1 ratio) administered by subcutaneous injection 
once monthly for 6 months. Patients randomized to the 120-mg dose received a loading dose of 240 mg (2 
injections of 120 mg each) at the first dosing visit. To achieve balance among groups, randomization was 
stratified by country and migraine frequency (<8 vs. ≥8 MHDs/month) at baseline.  All injections were 
administered by the investigator sites’ trained personnel. In order to preserve blinding, galcanezumab and 
matching placebo (ie; excipients only) were supplied as 1-mL, single-dose, prefilled, disposable manual 
syringes with study-specific labels. The syringes were visibly indistinguishable from each other. Patients 
in all groups received two injections at each dosing visit to preserve blinding throughout the study.    
Outcome Measures 
Efficacy analyses were performed in the intent-to-treat (ITT) population, where each randomized patient 
had received at least one dose of galcanezumab or placebo. The primary objective was to assess whether 
at least one of the studied dosing regimens of galcanezumab was superior to placebo in the prevention of 
migraine headache in patients with episodic migraine. The primary analysis evaluated the efficacy of each 
dosing regimens of galcanezumab compared with placebo on the overall mean change from baseline in 
the number of monthly MHDs during the 6-month treatment phase, based on the ePRO data. The key 
secondary outcome measures, analyzed with control for multiple testing, were the following: 
 The mean proportion of patients with reduction from baseline of  ≥50%, ≥75%, and 100% in 
monthly MHDs during the 6-month double-blind treatment phase. Response rate was defined 
as the percentage of patients meeting predefined thresholds (ie; ≥50%, ≥75%, and 100%) in 
the reduction from baseline in the number of MHDs for each month, and the overall 
percentage of patients meeting these thresholds averaged over months 1 through 6 were 
analyzed.  
 The mean change from baseline in the Role Function-Restrictive (R-FR) domain score of the 
Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v2.1), as an average of 
Months 4 to 6. 
 The overall mean change from baseline in the number of MHDs with acute migraine 
medication use during the 6-month double-blind treatment phase. 
 The mean change from baseline in the Patient Global Impression of Severity (PGI-S) rating 
(average of Months 4 to 6). 
A secondary, but non-key, outcome measure that is included in the current manuscript is the Migraine 
Disability Assessment (MIDAS) total score at Month 6.  
Safety and Tolerability  
The safety population consisted of all randomized patients who received at least one dose of 
galcanezumab or placebo. Adverse events were coded by Medical Dictionary for Regulatory Activities 
(version 19.1). The safety parameters reported in the present manuscript are the treatment-emergent 
adverse events (TEAEs), serious adverse events (SAEs), deaths, discontinuations due to adverse events, 
discontinuation rates, vital signs, and body weight. The topic of immunogenicity is also briefly discussed. 
A comprehensive safety report is in preparation as a separate manuscript. 
Assessments  
The ePRO daily diary was used to record headache and other migraine symptoms. Based on the diary 
data, using an automated algorithm, the days were categorized as MHDs (including probable MHD). A 
probable migraine is defined as a headache with or without aura and lasting ≥30 minutes but missing one 
of the migraine features in the ICHD-3 beta criteria (3). The monthly number of MHDs with acute 
migraine medication use was obtained through the ePRO diary, and the PGI-S, MQS, and MIDAS 
assessments were performed at the study site at every monthly visit for PGI-S and MSQ and on Months 3 
and 6 for MIDAS with the use of a slate device.  
Statistical Analyses 
The changes from baseline to each scheduled postbaseline measurement for continuous efficacy measures 
were estimated for each treatment from mixed effect model repeat measurements (MMRM) analyses. 
This model included the fixed, categorical effects of treatment, pooled country, month, and treatment-by-
month interaction, as well as the continuous, fixed covariates of baseline value and baseline-by-month 
interaction. The primary endpoint of overall mean change in monthly MHDs was estimated as the main 
effect of treatment (each galcanezumab dose group and placebo) during the 6-month treatment phase. 
This provided the average treatment effect across the 6-month double-blind treatment phase.  
When the objective of the continuous secondary efficacy measures was to assess overall mean change 
during the 6-month treatment phase, the endpoint for comparing galcanezumab with placebo was the 
main effect of treatment from the MMRM analysis across Months 1 to 6. Change from baseline of 
continuous variables with repeated measures included the change from baseline for MHD with acute 
medication use for Months 1 to 6, as well as MSQ R-FR and PGI-S for Months 4 to 6. The categorical 
longitudinal efficacy measures of ≥50%, ≥75%, and 100% reduction from baseline in the number of 
monthly MHD from Months 1 to 6 were analyzed with a categorical, pseudo-likelihood-based repeated 
measures analysis. A superchain (multiple testing) procedure was used to ensure strong control of the 
familywise type I error rate for the primary and key secondary endpoints (Figure 2) (21). According to the 
specified procedure, testing of key secondary endpoints was to commence in a sequential fashion 
following testing of the primary endpoint.  The superchain procedure provides appropriate adjustment for 
multiple testing across the two dose levels and all primary and key secondary endpoints.  Categorical 
safety measures were analyzed using the Fisher’s exact test. All statistical analyses were performed with 
the use of SAS Enterprise Guide 7.1 (SAS Institute, Cary, NC). 
Results 
Patient Disposition and Baseline Characteristics 
A total of 1696 patients entered study screening, and 922 were randomized (Figure 3). The most common 
reason for patients failing the screening phase was not having the required number of MHDs. A total of 
915 patients received at least one dose of galcanezumab or placebo and comprised the ITT population, 
and 785 patients (85.8%) completed the double-blind treatment phase of the study. Overall, a total of 129 
(14.1%) patients discontinued during Study Period III. The most common reason for discontinuation was 
the patient’s decision to withdraw, accounting for 64 (7%) patients. Adverse events (AEs) accounted for 
the discontinuation of 8 (1.7%) placebo patients, 5 (2.2%) galcanezumab 120 mg patients, and 9 (4.0%) 
galcanezumab 240 mg patients and were not significantly different among the groups. In addition, 10 
(2.2%) placebo patients, 7 (3.0%) galcanezumab 120 mg patients, and 0 (0%) galcanezumab 240 mg 
patients were lost to follow-up.  
Mean age (standard deviation [SD]) of the study population was 41.9 (11.1) years, and the population was 
largely female (85.4%) and white (70.3%), and North American (48.7%) or European (26.3%). At 
baseline, approximately 66.9% of patients had 8 or more MHDs per month. The majority (65.5%) of the 
patients had prior experience with migraine preventive treatments, and 14.3% of them had previously 
failed 2 or more preventive medications. The baseline characteristics for each treatment group are 
summarized in Table 1.  
Efficacy and Measures of Functioning 
Galcanezumab at both doses met the primary and all key secondary endpoints (Table 2). A total of 896 of 
the 915 ITT patients were included in the efficacy analyses. Nineteen patients were excluded because they 
did not meet the requirement of having at least one non-missing post-baseline monthly MHD. The least 
squares (LS) mean change from baseline in MHDs over the 6-month study period for galcanezumab 120 
and 240 mg were significantly (p<.001) reduced relative to placebo (Figure 4A). These reductions 
represent changes of -2.02 (±0.27) and -1.90 (±0.27) monthly MHDs, relative to placebo, for 
galcanezumab 120 and 240 mg, respectively. The reduction in monthly MHDs for the galcanezumab 120 
and 240 mg groups separated from placebo at a statistically significant level at Month 1 and maintained 
that separation throughout the treatment phase of the study (Figure 4B).  
Significantly (p<.001) greater reductions in monthly MHDs response rates of ≥50% were observed in 
59% and 57% of patients in the galcanezumab 120 and 240 mg groups, respectively, when compared to 
the 36% in the placebo group (Figure 5). The percentages of patients reporting ≥75% and 100% response 
rates are provided in Figure 5. Galcanezumab 120 and 240 mg resulted in significant (p<.001) reductions 
in MHDs with acute migraine medication use compared to the placebo group (Figure 6).  
Treatment with both dosing regimens of galcanezumab was associated with reduced functional 
impairment due to migraine as measured in the MSQ RF-R. Both galcanezumab 120 and 240 mg 
significantly (p<.001) improved the LS means of the MSQ RF-R score averaged over Months 4 through 6 
(Figure 7). Both galcanezumab groups showed improvement in patients’ global impression of severity of 
their disease as assessed by PGI-S rating (Figure 8). The LS mean change in PGI-S ratings for the 
galcanezumab 120 and 240 mg groups were significantly (p=.002 and p=.012, respectively) greater than 
in the placebo group. In addition, both treatment groups of galcanezumab significantly (p<.001) improved 
total MIDAS scores at Month 6, which was the prespecified time point of interest, compared to placebo 
group (Figure 9).  
Safety and Tolerability 
TEAEs were reported by 147 (65.0%) and 163 (71.5%) of the patients receiving galcanezumab 120 and 
240 mg, respectively, and by 287 (62.3%) placebo patients (Table 3). The proportion of patients reporting 
a TEAE from the galcanezumab 240 mg group was significantly (p<.05) greater than that of the placebo 
group. No deaths were reported in any of the treatment groups, and the percentage of SAEs, which were 
1.1%, 2.2%, and 3.1% for placebo, galcanezumab 120 mg, and galcanezumab 240 mg groups, 
respectively, did not differ significantly (Table 3). Twenty SAEs were reported by 17 patients. Five 
placebo patients had gallbladder polyp, hemorrhoids, migraine, and suicide attempt. Foot fracture, rib 
fracture, and road traffic accident were all reported by 1 placebo patient. Five patients in the 
galcanezumab 120 mg group had adenocarcinoma of the cervix, bladder dysfunction, gastritis, pharyngitis 
bacterial, and rectal polyp; and 7 patients in the galcanezumab 240 mg group reported acute myocardial 
infarction, cholelithiasis, generalized tonic-clonic seizure, influenza, meniscus injury, and transient 
ischemic attack. Disorientation and pyrexia were both reported by 1 patient in the galcanezumab 240 mg 
group. None of these SAEs were reported by more than 1 patient. The percentage of patients 
discontinuing the study because of adverse effects were 1.7% (8 patients reporting atopic dermatitis, 
facial pain, fatigue, hypertension, pain in extremity, suicide attempt, syncope, vertigo), 2.2% (5 patients 
reporting injection site reaction, adenocarcinoma of the cervix, bronchiectasis, gastritis, pruritic rash), and 
4.0% (9 patients reporting injection site reaction, chest discomfort, hepatic enzyme increased, infection, 
influenza like illness, nasopharyngitis, skin ulcer) for the placebo, galcanezumab 120 mg, and 
galcanezumab 240 mg groups, respectively, and did not differ significantly among the 3 treatment groups 
(Table 3). The most commonly reported TEAE among the 3 treatment groups was injection site pain 
(9.3%, 8.8%, and 8.5% for the galcanezumab 120 mg, galcanezumab 240 mg, and placebo groups, 
respectively), which was not significantly different among the groups. Commonly reported TEAEs that 
showed significant differences for either or both dosing regimens of galcanezumab compared to placebo 
were injection site reaction, injection site erythema, injection site pruritus, and injection site swelling 
(Table 4). No statistically significant differences were found in mean change from baseline for pulse rate, 
body weight, systolic/diastolic blood pressure, and body temperature between the galcanezumab 
treatment groups and placebo.  
Immunogenicity 
At baseline, prior to randomization, anti-drug antibodies (ADAs) were detected in 8.4%, 8.1%, and 11.2% 
of patients in the placebo, galcanezumab 120 mg, and galcanezumab 240 mg groups, respectively. There 
were 19 (8.6%), 11 (5.1%), and 2 (0.5%) patients in the galcanezumab 120 mg, galcanezumab 240 mg, 
and placebo groups, respectively, with treatment-emergent ADA. The difference between each 
galcanezumab treatment group and placebo was statistically significant (p<.001). Among all treatment-
emergent ADA+ patients, 29 of them had neutralizing ADAs present. The ADA titers were generally low. 
Titers ranged from not detectable to a maximum of 1:1280, which occurred in 4 patients. Patients who 
were ADA+ at any time and who also reported a TEAE had titers ranging from 1:10 to 1:640. Treatment-
emergent ADAs or neutralizing ADAs had no impact on either safety or efficacy. 
  
Discussion 
Treatment with the currently available migraine prevention drugs is associated with a relatively poor 
tolerability and low rates of patient satisfaction (8,9). Consequently, the prevention of migraine remains 
an important unmet clinical need. The results of this large Phase 3 randomized clinical trial demonstrate 
that galcanezumab is well-tolerated and efficacious in preventing migraine headache. 
Both dose regimens of galcanezumab met the primary and all key secondary endpoints. Galcanezumab 
significantly reduced the monthly MHDs relative to placebo within the first month of the trial and the 
reduction was maintained throughout the 6-month treatment period. Mean reduction in MHD observed in 
the galcanezumab treatment group translates into an annualized gain of approximately 7 weeks of 
migraine-free days. In addition, 59% and 57% of patients who were treated with galcanezumab 120 or 
240 mg, respectively, relative to 36% of those receiving placebo, had response rates of ≥50%, a well-
established benchmark indicating a clinically meaningful result (22). Similarly, ≥75% and 100% response 
rates were also statistically significantly greater in both glacanezumab treatment groups relative to 
placebo. Treatment with both dose regimens of galcanezumab was also associated with a significant 
decrease in the use of acute migraine medications. This is an important consideration because their 
overuse may lead to the development of medication overuse headache (3,10). Galcanezumab was also 
found to be superior to placebo in reducing the migraine-related impairment in functioning, as indicated 
by the significant improvement relative to placebo, as measured by the MSQ R-FR and the MIDAS total 
scores. The patients’ global impression of severity of disease as determined by the PGI-S scale was also 
significantly improved relative to placebo by both dose regimens of galcanezumab. Taken together, the 
results of this global clinical trial indicate that (1) treatment with galcanezumab demonstrates a clinically 
meaningful level of efficacy in preventing migraine headaches in patients with episodic migraine and (2) 
replicate the findings of the identically designed North American study (EVOLVE-1) (23). 
Injection site pain, the most common TEAE, was reported by approximately 9% of patients, regardless of 
whether treated with galcanezumab or placebo. TEAEs significantly more commonly reported by the 
galcanezumab-treated patients, relative to those treated with placebo, were all injection site related: 
injection site reaction, injection site pruritus, injection site swelling, and injection site erythema. Most of 
these TEAEs were reported to be mild to moderate. No reported serious TEAEs were related to injection 
site, and only 4 patients receiving galcanezumab discontinued the study due to injection site reaction. 
Discontinuations due to TEAEs were low, as was the rate of SAEs, and they did not differ among the 
treatment groups. Together, these results show that galcanezumab is well tolerated, with the small number 
of patients experiencing relatively minor injection-site related adverse effects.  
Galcanezumab presents a promising investigational drug for migraine prevention. By the end of the 6-
month treatment period, more patients receiving placebo than those receiving galcanezumab discontinued 
from the study for any reason. Similarly, the number of placebo-treated patients who discontinued the 
study due to lack of efficacy was 3 times as high as the corresponding number of the galcanezumab-
treated patients. These results are especially encouraging when one considers that as many as two-thirds 
of patients using currently available preventive therapies discontinue their use because of poor tolerability 
or lack of efficacy over a 6-month period (7-9). Notably, this study also included patients who had tried 
and failed several preventive treatments from up to two different classes.  
Limitations of the study include certain restrictions in the inclusion criteria that may limit the 
generalizability of the results. Patients with serious medical or psychiatric conditions, high body mass 
index, substantial opioid use, and high risk for major cardiovascular events were excluded. Although the 
study was of a relatively large size and long duration, it may not be sufficient to detect possible rare 
adverse events or long-term risks.  
Conclusions 
Galcanezumab treatment was associated with a statistically significant and clinically meaningful 
reduction in monthly MHDs at doses of 120 and 240 mg given subcutaneously once monthly. Moreover, 
patients treated with either dose of galcanezumab reported a reduction in the migraine-related impairment 
of function and a significant reduction in migraine-related disability, while also reducing the use of acute 
migraine medications. Galacanezumab treatment was safe and well tolerated. No clinically meaningful 
differences in either efficacy or safety were found between the two galcanezumab dose regimens. The 
results of this investigation confirm findings from several previously published migraine prevention 
studies of galcanezumab.  
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Clinical Implications  
 Galcanezumab is safe and efficacious in preventing migraine.  
 Galcanezumab reduces migraine-related disability and impairment in functioning. 













Patient Demographics    
Age, years, mean (SD) 42.3 (11.3) 40.9 (11.2) 41.9 (10.8) 
Gender (female), % 85.3 85.3 85.7 
Race (white), % 70.5 71.9 68.2 
Disease Characteristics at Baseline    
MHD per month,† mean (SD) 9.2 (3.0) 9.07 (2.9) 9.06 (2.9) 
MHD with acute medication use per 
month,* mean (SD) 
7.6 (3.4) 7.47 (3.3) 7.47 (3.3) 
MIDAS total score, mean (SD) 34.3 (31.0) 30.9 (27.9) 32.8 (28.8) 
MSQ RF-R,* mean (SD) 51.4 (15.7) 52.5 (14.8) 51.7 (16.3) 
PGI-S,* mean (SD) 4.3 (1.2) 4.1 (1.2) 4.2 (1.2) 
Duration of migraine illness, years, 
mean (SD) 
21.2 (12.8) 19.93 (11.7) 20.01 (12.1) 
    
Migraine attacks per month, mean (SD) 5. 7 (1.8) 5.54 (1.8) 5.66 (1.8) 
Number of headache days, mean (SD) 10.7 (3.5) 10.56 (3.4 10.74 (3.7) 
MHD category ≥8, % 66.6 66. 7 67.7 
Prior preventive treatment, % 64.6 68.0 64.6 
≥2 failed preventive treatments mean 
(SD) 
63 (13.7) 34 (14.7) 34 (15.3) 
Region    
North Americaa, % 48.6 48.5 49.3 
Europe, % 26.5 26.0 26.5 
Other, % 25.0 25.5 24.2 
 
†Primary and *key secondary outcome measures. Other characteristics may be associated with non-key 
secondary measures and (except for MIDAS) fall outside the scope of this manuscript. They will be 
discussed in an upcoming publication. aNorth America includes Mexico and the Unites States. 
Abbreviations: MHD=migraine headache day; MIDAS=Migraine Disability Assessment; MSQ RF-
R=Migraine-Specific Quality of Life Questionnaire Role Function-Restrictive; N=the intent-to-treat 
























p-value LSM (SE) 
(95% CI) 
p-value 





<0.001 -4.2 (0.3) 
(-4.7,-3.7) 
<0.001 0.026 S 
Mean proportion (as %) 
of responders 







<0.001 56.5 (2.5) 
(52,61) 






<0.001 34.3 (2.3) 
(30, 39) 






<0.001 13.8 (1.5) 
(11, 17) 
<0.001 0.025 S 







<0.001 -3.6 (0.2) 
(-4.1,-3.2) 






<0.001 27 (1.2) 
(24.7,29.3) 
<0.001 0.025 S 





<0.001 -20.2 (1.6) 
(-23.4,-17.1) 






0.002 -1.2 (0.1) 
(-1.3, -1.0) 
0.012 0.025 S 
 
Data are presented as the change from baseline. P-values are the given versus placebo. The adjusted 
significance level represents the significance threshold adjusted for multiplicity. If p-value is less than or 
equal to the adjusted significance level, then the results are statistically significant after adjustment for 
multiplicity. MIDAS was not a key secondary outcome measure, and was not subjected to multiplicity 
adjustment. 
 
Abbreviations: CI=Confidence intervals; LSM=least squares mean; MHD=migraine headache day; 
MIDAS=Migraine Disability Assessment; MSQ RF-R=Migraine-Specific Quality of Life Questionnaire 
Role Function-Restrictive; N=the intent-to-treat population for each dosing regimen; N/A=Not 
applicable; PGI-S=Patient Global Impression of Severity; PL=placebo; S=Significant; SE=standard error, 
Sig.=significance. 
  
Table 3. Overview of Adverse Events 
 






n (%) p-value 
240 mg 
N=228 
n (%) p-value 
TEAEs 287 (62.3) 147 (65.0) 0.501 163 (71.5) 0.017 
Serious AEs 5 (1.1) 5 (2.2) 0.31 7 (3.1) 0.07 
Deaths 0 (0.0) 0 (0.0)  0 (0.0)  
Discontinuation due to 
AEs 
8 (1.7) 5 (2.2) 0.767 9 (4.0) 0.114 
 
 P-values vs. placebo. No p-values were computed for “Deaths”, since all values were 0.Abbreviations: 





Table 4. Treatment-Emergent Adverse Events ≥2% Galcanezumab Total 
 











n (%) p-value 
Subjects with ≥1 
TEAE 
287 (62.3) 147 (65.0) .004 163 (71.5) <.001 
Injection site pain 39 (8.5) 21 (9.3) .774 20 (8.8) .89 
Injection site 
reaction 
0 (0.0) 7 (3.1) <.001 18 (7. 9) <.001 
Injection site 
erythema 
4 (0.9) 6 (2.7) .089 7 (3.1) .048 
Injection site 
pruritus 
0 (0.0) 6 (2.7) .001 7 (3.1) <.001 
Injection site 
swelling 
0 (0) 5 (2.2) .004 1 (0.4) .331 
Nasopharyngitis 41 (8.9) 19 (8.4) .886 16 (7.0) .464 
Upper respiratory 
tract infection 
16 (3.5) 13 (5.8) .164 12 (5.3) .306 
Dizziness 10 (2.2) 8 (3.5) .314 7 (3.1) .448 
Influenza 14 (3.0) 3 (1.3) .203 10 (4.4) .381 
Fatigue 12 (2.6) 6 (2.7) 1.000 5 (2.2) 1.000 
Diarrhea 11 (2.4) 7 (3.1) .615 3 (1.3) .407 
 
 
 P-values vs. placebo.Abbreviations: N=the safety population for each dosing regimen; TEAE=treatment-







Figure 1. Study Protocol. aPatients randomized to the galcanezumab 120 mg dose received a loading dose 
of 240 mg at the first injection only (Visit 3). Abbreviation: SP=Study Period; X indicates visits when 
dosing occurred. 
Figure 2. For the superchain multiple testing procedure, Dunnett’s test was used to test the primary null 
hypotheses.  When at least one of the 2 primary null hypotheses was rejected, the Hochberg procedure 
was to be used to test the 50% and 75% response rate endpoints at the corresponding dose(s).  Upon 
rejection of these null hypotheses, the Bonferroni-Holm procedure was to be used to test the change in the 
use of acute migraine treatment and the change in functioning for the MSQ, at the corresponding doses.   
Following rejection of these null hypotheses, the hypotheses of 100% response rate and PGI-S were 
tested sequentially at the corresponding doses.  When all null hypotheses for a single dose were rejected, 
available alpha was to be propagated to the other dose for continued testing of available nonrejected null 
hypotheses.  In the diagram, propagation weights are denoted along edges connecting boxes, and families 
of hypotheses are shown in the boxes. 
Abbreviations: acute meds=MHD with the use of acute treatment; MHD=the number of monthly migraine 
headache days (mean change from baseline); MSQ RF-R=Migraine-Specific Quality of Life 
Questionnaire Role Function-Restrictive; PGI-S=Patient Global Impression-Severity; RR=response rate 
in MHD. 
Figure 3. CONSORT diagram showing patient disposition throughout the trial. *p<.05 (vs. placebo); 
†p<.05 (vs. galcanezumab 120 mg).  
Figure 4a. The overall LS mean change from Months 1 through 6 in monthly migraine headache days. 
The inset table shows the LS mean change from placebo for both doses of galcanezumab. Figure 4b. The 
LS mean change at each of the Months 1 through 6 in monthly migraine headache days. ***p<.001 (vs. 
placebo).   
Abbreviations: LS=least squares; SE=standard error. 
Figure 5. The mean percent of patients with ≥50%, ≥75%, and 100% reductions in monthly migraine 
headache days. ***p<0.001 (vs. placebo). 
Abbreviation: SE=standard error. 
Figure 6. The LS mean change in migraine headache days with the use of acute migraine medications. 
***p<0.001 (vs. placebo). 
Abbreviations: LS=least squares; SE=standard error. 
Figure 7. The LS mean change in the Migraine-Specific Quality of Life Questionnaire Role Function-
Restrictive domain. ***p<0.001 (vs. placebo). 
Abbreviations: LS=least squares; SE=standard error. 
Figure 8. The LS mean change in the Patient Global Impression-Severity rating. **p<0.01; *p<0.05 (vs. 
placebo). 
Abbreviations: LS=least squares; SE=standard error. 
Figure 9. The LS mean change in the Migraine Disability Assessment score. ***p<0.001 (vs. placebo). 
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